-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$45.00101.25% Upside
Recent Analyst Forecasts and Stock Ratings
BridgeBio Pharma, Inc. Frequently Asked Questions
-
What analysts cover BridgeBio Pharma, Inc.?
BridgeBio Pharma, Inc. has been rated by research analysts at Citigroup, Leerink Partners, Piper Sandler, Mizuho Securities, Raymond James, BMO Capital in the past 90 days.